Jpmorgan Chase & CO G1 Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Dec 26, 2024	BUY	$2.2 - $4.98 $46,263 - $104,724	21,029 New	21,029 $47,000
Q2 2024 Aug 12, 2024	SELL	$2.2 - $4.98 $73,931 - $167,352	-33,605 Reduced 61.51%	21,029 $47,000
Q1 2024 Dec 26, 2024	BUY	$2.1 - $4.83 $114,731 - $263,882	54,634 New	54,634 $236,000
Q1 2024 May 10, 2024	BUY	$2.1 - $4.83 $114,206 - $262,674	54,384 Added 21753.6%	54,634 $236,000
Q4 2023 Dec 26, 2024	BUY	$1.12 - $3.73 $280 - $932	250 New	250 $0
Q4 2023 Feb 12, 2024	SELL	$1.12 - $3.73 $10,203 - $33,980	-9,110 Reduced 97.33%	250 $0
Q3 2023 Nov 14, 2023	SELL	$1.22 - $2.67 $2.57 Million - $5.62 Million	-2,106,513 Reduced 99.56%	9,360 $13,000
Q2 2023 Aug 11, 2023	SELL	$2.46 - $3.14 $82,786 - $105,670	-33,653 Reduced 1.57%	2,115,873 $5.27 Million
Q1 2023 May 11, 2023	BUY	$2.57 - $8.16 $292,733 - $929,456	113,904 Added 5.6%	2,149,526 $5.76 Million
Q4 2022 Feb 13, 2023	SELL	$5.19 - $13.5 $42,303 - $110,038	-8,151 Reduced 0.4%	2,035,622 $11.1 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $16.99 $442,944 - $1.46 Million	-85,676 Reduced 4.02%	2,043,773 $25.5 Million
Q2 2022 Aug 11, 2022	BUY	$4.04 - $8.51 $128,051 - $269,732	31,696 Added 1.51%	2,129,449 $10.5 Million
Q1 2022 May 11, 2022	SELL	$7.6 - $11.02 $349,075 - $506,159	-45,931 Reduced 2.14%	2,097,753 $15.9 Million
Q4 2021 Feb 10, 2022	SELL	$10.16 - $16.17 $975,309 - $1.55 Million	-95,995 Reduced 4.29%	2,143,684 $21.9 Million
Q3 2021 Nov 12, 2021	BUY	$13.16 - $22.47 $29.5 Million - $50.3 Million	2,239,679 New	2,239,679 $30.1 Million

3.55M

11.7K

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.